Biocon reported a sharp turnaround in Q2FY26, with profit soaring 428% YoY to ₹85 crore and revenue rising 20% to ₹4,296 crore. Growth was led by strong biosimilar and generics demand. The company reduced debt, opened its first US OSD unit, and began Semaglutide filings in global markets, strengthening long-term prospects.